Sentiment Trading

RAPT Therapeutics Inc. is set to announce topline results from a Phase 2 trial of its investigational compound RPT904 for the treatment of Chronic Spontaneous Urticaria (CSU) on October 20, 2025.

RAPT Therapeutics is a pharmaceutical company specializing in immunology and cancer treatment, with a market capitalization of approximately $142.54 million.

RAPT Therapeutics, Inc. is a pioneering pharmaceutical company at the forefront of developing innovative solutions to combat cancer and allergic inflammatory diseases through cutting-edge research and technology.

RAPT Therapeutics, Inc. is a pharmaceutical company focused on developing treatments for cancer and allergic inflammatory diseases through immunology, small molecule drug discovery, and computational biology services.

RAPT Therapeutics is a pharmaceutical company specializing in immunology and small molecule drug discovery, focused on developing treatments for cancer and allergic inflammatory diseases.